-
Mashup Score: 0TCT 2024 - 17 day(s) ago
Join us at the Boston Scientific Engagement Hub at TCT 2024 for exclusive expert discussions, data-based learning, hands-on training, receptions and more.
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 3TCT 2024 - 18 day(s) ago
Join us at the Boston Scientific Engagement Hub at TCT 2024 for exclusive expert discussions, data-based learning, hands-on training, receptions and more.
Source: www.bostonscientific.comCategories: General Medicine News, Cardiology News and JournTweet-
Tomorrow at #TCT2024: Drs. Singh, Price, Huded & Gafoor will host a discussion on #LAAC key insights including clinical data, unmet needs, and procedural advancements. Join them: https://t.co/AOzDktUabJ #Sponsored https://t.co/uwAQdAn7Ba
-
-
Mashup Score: 0TCT 2024 - 18 day(s) ago
Join us at the Boston Scientific Engagement Hub at TCT 2024 for exclusive expert discussions, data-based learning, hands-on training, receptions and more.
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
Don’t forget, this week at #TCT2024, make sure to catch both the PROTECTED TAVR Trial on Tuesday, October 29th and the ACURATE IDE Trial session Wednesday, October 30th. Get the latest insights from these Late-breaking Clinical Trials! https://t.co/3f7CoACVBi https://t.co/4LBk1Uilpk
-
-
Mashup Score: 17The OPTION Clinical Trial - 20 day(s) ago
The OPTION Clinical Trial is a randomized controlled trial comparing the safety and effectiveness of left atrial appendage closure (LAAC) to oral anticoagulation (OAC) therapy for stroke protection in post-ablation patients with atrial fibrillation. This study involves an investigational device called the WATCHMAN FLX™ *. The number of subjects expected to participate in the study will be 1600 at up to 130 investigational centers around the world. Below is an overview of the study. WATCHMAN FLX is an FDA
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
Don’t miss results from the OPTION Clinical Trial, presented at #AHA24! This pivotal study compares the safety & effectiveness of the WATCHMAN FLX™ #LAAC device to oral anticoagulation for stroke protection post-ablation. Learn more about OPTION: https://t.co/1TBMFCAKBm https://t.co/xNix7R5eDo
-
-
Mashup Score: 5Trial Rationale - 22 day(s) ago
Current guidelines state th at non-vitamin K antagonist oral anticoagulant (NOAC) therapy is the first line option for treatment of stroke risk reduction in non‑valvular atrial fibrillation (NVAF) patients. However, bleeding risk on these therapies compounds year over year, and are comparable across current pharmacotherapy options. *The HAS-BLED scoring system predicts a patients risk of major bleeding in patients with atrial fibrillation. **Assumes constant risk despite increasing age, and bleeding risk
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
"The more data that we have, the better off we are.” We’re excited about the recent launch of the SIMPLAAFY clinical trial and energized about the future of #LAAC therapy and post-implant care for patients with AF. For more on SIMPLAAFY, visit https://t.co/wCFX6UGNvY https://t.co/zKJxdlkv7n
-
-
Mashup Score: 4TCT 2024 - 22 day(s) ago
Join us at the Boston Scientific Engagement Hub at TCT 2024 for exclusive expert discussions, data-based learning, hands-on training, receptions and more.
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
#TCT2024 will be here soon! Come explore the future of cardiology. Visit us in our Tech Suite at Hub 1 and learn more about how we are advancing patient care. See all the events here: https://t.co/NSmVnYgtwY https://t.co/fIf9Ko5BZz
-
-
Mashup Score: 8TCT 2024 - 22 day(s) ago
Join us at the Boston Scientific Engagement Hub at TCT 2024 for exclusive expert discussions, data-based learning, hands-on training, receptions and more.
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
Don't miss out on our late-breaking clinical trials at #TCT2024! Be sure to join us both Tuesday, October 29th for the PROTECTED TAVR Trial and Wednesday, October 30th for the ACURATE IDE Trial. See full event details: https://t.co/SRvAkcJ9Z5 https://t.co/0YgsD7tQ37
-
-
Mashup Score: 26Mapping Integration - FARAPULSE™ PFA System - 23 day(s) ago
Upon approval (anticipated 2024 2H), FARAPULSE will allow users to visualize their approach like never before. The FARAVIEW™ Software Module will offer integrated mapping to visualize catheter placement, shape and rotation of the magnetically-tracked FARAWAVE™ NAV Pulsed Field Ablation Catheter.
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
See how PFA workflows can be optimized with an integrated single-catheter solution to map and ablate, with FARAVIEW™ and FARAWAVE™ NAV. https://t.co/Vlx3IWOAeE #PulsedFieldAblation Safety Link: https://t.co/ZuxokzUirD https://t.co/V3YjjUJWiH
-
-
Mashup Score: 0
FARAPULSE Pulsed Field Ablation System Indications, Safety and Warnings
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
Safety Info: https://t.co/nGo7EL6fn5
-
-
Mashup Score: 1Mapping Integration - FARAPULSE™ PFA System - 28 day(s) ago
Upon approval (anticipated 2024 2H), FARAPULSE will allow users to visualize their approach like never before. The FARAVIEW™ Software Module will offer integrated mapping to visualize catheter placement, shape and rotation of the magnetically-tracked FARAWAVE™ NAV Pulsed Field Ablation Catheter.
Source: www.bostonscientific.comCategories: General Medicine News, PayerTweet-
Learn More: https://t.co/dvdTIMWkVA
-
Learn more: https://t.co/Wl8Zv86UTy